WALTHAM, Mass., Oct. 1, 2021 /PRNewswire/ -- Thermo Fisher
Scientific Inc. (NYSE:TMO), the world leader in serving science,
today announced that it has assumed operational responsibility for
a new biologics manufacturing site in Lengnau, Switzerland as part of its strategic
partnership with CSL Limited announced last year. The Lengnau
site will become part of Thermo
Fisher's global biologics manufacturing network, and
approximately 200 employees will join Thermo Fisher.
The Lengnau site is a 1.5 million square-foot facility that will
leverage highly flexible bioproduction technologies, including both
single-use and stainless steel with up to 12,500L bioreactor
capacity. This will provide biopharma companies with a pathway from
development to large-scale production as manufacturing needs
evolve.
"We are excited to add the new Lengnau site to our global
biologics manufacturing network and we are thrilled to welcome more
than 200 new colleagues to Thermo
Fisher," said Michel Lagarde, executive vice president
of Thermo Fisher Scientific. "Through our partnership with CSL,
this site further strengthens our unique customer value proposition
to leverage our scale and depth of capabilities for pharma and
biotech customers. With the addition of new high-volume
stainless-steel capabilities in Lengnau, we are enabling our
customers to start their projects with us and stay with us as their
manufacturing requirements grow."
Following completion of site construction in 2022, Thermo
Fisher will initially support manufacturing of CSL's
next-generation recombinant factor IX product Idelvion® for
patients with hemophilia B. Over time, Thermo
Fisher plans to expand the use of the site to include
additional biopharma customers.
The Lengnau site is an important expansion of Thermo Fisher's biologics manufacturing network
that includes Princeton, NJ and
St. Louis, MO, USA; Groningen, NL;
Brisbane, AU; and Hangzhou, China.
About Thermo Fisher Scientific
Thermo Fisher
Scientific Inc. is the world leader in serving science, with annual
revenue of approximately $35 billion.
Our Mission is to enable our customers to make the world healthier,
cleaner and safer. Whether our customers are accelerating life
sciences research, solving complex analytical challenges, improving
patient diagnostics and therapies or increasing productivity in
their laboratories, we are here to support them. Our global team of
more than 90,000 colleagues delivers an unrivaled combination of
innovative technologies, purchasing convenience and pharmaceutical
services through our industry-leading brands, including Thermo
Scientific, Applied Biosystems, Invitrogen, Fisher Scientific,
Unity Lab Services and Patheon. For more information, please
visit www.thermofisher.com.
Media Contact Information:
Ron O'Brien
Phone: 781-622-1242
E-mail: ron.obrien@thermofisher.com
Investor Contact Information:
Raf Tejada
Phone: 781-622-1356
E-mail: rafael.tejada@thermofisher.com
View original content to download
multimedia:https://www.prnewswire.com/news-releases/thermo-fisher-scientific-opens-biologics-manufacturing-site-in-lengnau-switzerland-301389289.html
SOURCE Thermo Fisher Scientific